Rat-study gives new hope to Parkinson’s patients

A small Danish biotech company has been granted millions from SEED Capital and Novo Seeds for a new study.

Foto: Torben Stroyer/JP

Following successful studies with rats, the small Danish biotech Company, Concit Pharma, is now trying to find the solution to a highly debilitating side-effect from the medical treatment of Parkinson’s patients. The solution is to be found in the combination of existing drugs and two major investors are ready with capital injection, the company reveals in a press release.

 “Concit Pharma has gained the opportunity to help remedy the debilitating movement disorders associated with Parkinson’s disease within a number of years. In pre-clinical trials the company has documented significant effects of treating this disorder with a combination of already known drugs, and has now raised € 1.3 million to pursue this path further,” CEO John Bondo Hansen and co-founder Mikael Thomsen writes in the statement.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier